Paper8769637
Intracellular metabolism of zidovudine and stavudine in combination.
Hoggard P and 3 others. J Infect Dis, 1996. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. Intracellular metabolism of zidovudine and stavudine in combination. Papers, record 8769637. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8769637
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| HIV Infections | Major topic |
| HIV-1 | Major topic |
| Stavudine | Major topic |
| Zidovudine | Major topic |
| Cells, Cultured | |
| Drug Combinations | |
| Genetic Variation | |
| Humans | |
| Leukocytes, Mononuclear | |
| Phosphorylation |
Source PubMed
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 20000887 | Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. | Clin Pharmacokinet | 2010 | https://conductscience.org/library/papers/20000887 | PubMed |
| 17517847 | In vitro interactions between apricitabine and other deoxycytidine analogues. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17517847 | PubMed |
| 17242147 | Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17242147 | PubMed |
| 12126455 | Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection. | Paediatr Drugs | 2002 | https://conductscience.org/library/papers/12126455 | PubMed |
| 12019069 | Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12019069 | PubMed |
| 10595868 | Stavudine: an update of its use in the treatment of HIV infection. | Drugs | 1999 | https://conductscience.org/library/papers/10595868 | PubMed |
| 10320951 | Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. | Clin Pharmacokinet | 1999 | https://conductscience.org/library/papers/10320951 | PubMed |
| 9647345 | Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection. | Pharm Res | 1998 | https://conductscience.org/library/papers/9647345 | PubMed |
| 9491831 | Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro. | Br J Clin Pharmacol | 1998 | https://conductscience.org/library/papers/9491831 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8769637
GET https://conductscience.org/api/papers/v1/8769637/authors